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Abstract
AIM: To investigate the effect of hepatoma cells on 
up-regulation of programmed cell death-1 (PD-1), and 
the function of PD-1 on T cells.
METHODS: HepG2 or HepG2.2.1.5 cells were co-
cultured with a lymphoma cell line-Jurkat cells. PD-1 
expression was detected by flow cytometry. IL-2, 
INF-γ and IL-10 in culture supernatant were detected 
by enzyme-linked immunosorbent assay (ELISA). 
Cytotoxic action of T cells was determined by MTT 
reduction assay-direct mononuclear cell cytotoxicity 
assay.
RESULTS: The PD-1 expression on Jurkat cells 
increased by 16.17% ± 2.5% and 17.43% ± 2.2% 
after HepG2 or HepG2.2.1.5 cells were co-cultured for 
48 h. The levels of IL-2, INF-γ and IL-10 in the culture 
supernatant were 202.9 ± 53.0 pg/mL, 88.6 ± 4.6 
pg/mL and 63.7 ± 13.4 pg/mL respectively, which were 
significantly higher than those (102.9 ± 53 pg/mL, 39.3 
± 4.2 pg/mL, and 34.6 ±13.7 pg/mL) in the control 
group (P  < 0.05). The OD value for MTT assay in the 
blocking group (0.29 ± 0.06) was significantly higher 
than that (0.19 ± 0.09) in the control group (P  < 0.05). 
CONCLUSION: PD-1 expression on Jurkat cells is up-
regulated by hepatoma cells, cytokines and cytotoxic 
action are elevated after PD-1/PD-L1 is blocked.
© 2008 The WJG Press. All rights reserved.
Key words: Hepatoma cell; Programmed cell death-1; 
Protein expression; T cell function; Cytokine
Peer reviewers: Fabio Grizzi, PhD, Laboratories of 
Quantitative Medicine, Istituto Clinico Humanitas IRCCS, 
Via Manzoni 56, 20089 Rozzano, Milan, Italy; Dr. Ursula 
M Gehling, Department of Hepatobiliary Surgery and Visc, 
University Hospital Hamburg-Eppendorf, 20246 Hamburg, 
Germany
Chen J, Wu XJ, Wang GQ. Hepatoma cells up-regulate 
expression of programmed cell death-1 on T cells. World J 
Gastroenterol 2008; 14(44): 6853-6857  Available from: URL: 
http://www.wjgnet.com/1007-9327/14/6853.asp  DOI: http://
dx.doi.org/10.3748/wjg.14.6853
INTRODUCTION
Programmed cell death-1 (PD-1), a member of  the 
CD28 family, was first isolated from T cell hybridoma by 
subtractive hybridization in 1992[1], and is expressed on 
activated T and B cells[2]. PD-1 has been recently found 
to play a role in immunity regulation as an inhibitory 
co-signaling molecule[3]. Upon its ligands (PD-L1 and 
PD-L2) are ligated, PD-1 decreases T cell receptor (TCR)-
mediated proliferation, cytokine production and cytolytic 
activity[4-7]. Barber et al[8] showed that up-regulation 
of  PD-1 expression on T cells is associated with the 
exhaustion of  T cells in lymphocytic choriomeningitis 
virus (LCMV) infection. The number of  effective T cells 
increases and their function markedly improves when 
the interaction of  PD-1 and PD-L is blocked. It was 
reported that PD-1 also plays a significant role in some 
autoimmune diseases[9-11] and viral infectious diseases, 
especially in chronic infectious diseases caused by human 
immunodeficiency virus (HIV)[12-14], hepatitis C virus 
(HCV)[15,16] and hepatitis B virus (HBV)[17-19]. There is 
evidence that PD-1 suppresses immune activation in 
PD-1-deficient mice with autoimmune disease[20]. Single-
nucleotide polymorphisms at the PD-1 locus have also 
been identified in patients with autoimmune disorders 
such as systemic lupus erythematosus, rheumatoid 
arthritis, and type 1 diabetes[21].
Recent evidence from studies on tumors shows that 
the PD-1/PD-1 pathway might play a critical role in 
tumor immunity evasion[22-24]. PD-1 is up-regulated on 
tumor specific T cells and PD-L is up-regulated in tumor 
tissue[25-27]. As a result, the function of  tumor specific 
T cells is suppressed, leading to the immune escaping 
of  tumor cells, and the level of  mRNA and PD-L1 
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protein can be detected in tumor tissues[25-27]. In addition, 
PD-1/PD-L interaction promotes apoptosis of  T cells, 
induces clearance of  specific T cells, and ultimately 
inhibits the anti-tumor immunity response[27]. Blocking 
the interaction of  PD-1/PD-L with anti-PD-l antibody 
partially recovers the function of  tumor specific T cells.
It was reported that the expression of  PD-L can 
be induced by virus and cytokines such as IFN-α 
and INF-γ[28]. However, no evidence for the induced 
expression of  PD-1 is available. Liver, an important 
immune organ, plays a critical role in immune regulation 
although it is prone to induce immune tolerance in many 
cases. The present study was designed to investigate 
whether hepatoma cells (HepG2 and HepG2.2.1.5) 
induce expression of  PD-1 in T cells. The functional 
role of  PD-1/PD-L interaction was also studied.
MATERIALS AND METHODS
Cell culture
Jurkat cells were cultured in RPMI 1640 medium 
(Gibco, USA), supplemented with 10% fetal calf  serum, 
300 µg/mL glutamine, 100 U/mL penicillin and 100 
µg/mL streptomycin. HepG2.2.1.5 cells or HepG2 cells 
provide by Mountsinai Medical Center were cultured in 
complete DMEM (Gibco, USA) containing 380 µg/L 
G418.
Co-culture system
HepG2 and HepG2.2.1.5 cells were cultured in 6-well 
plates (5 × 105 cells/well) for 24 h and Jurkat cells 
(5 × 105 cells/well) were added and co-cultured for 48 h. 
The suspended cells were collected for analysis of  PD-1. 
Jurkat cells were cultured solitarily for 48 h as controls.
Analysis of PD-1 expression
Cell surface expression of  PD-1 was detected by flow 
cytometry after incubated with allophycocyanin (APC)-
conjugated anti-PD-1 antibodies (eBioscience). Cells 
were collected and suspended in PBS containing 1% 
fetal calf  serum (FCS). The cell density was adjusted 
to 1 × 106 cells/vial. After incubated with anti-PD-1 
antibodies or matching isotype controls at 37℃ for 
30 min, cells were washed with PBS and fixed in 2% 
paraformaldehyde for analysis. A total of  20 000 gated 
cells were analyzed on Becton Dickinson FACS (Becton 
Dickinson, USA) using the CELLQuestTM software.
Blockade of PD-1/PD-L1 interaction
Antibody against human PD-L1 (eBioscience) was 
used to block PD-L1. Jurkat cells were activated with 
phytohemagglutinin (PHA) (2 µg/mL, Sigma, USA) and 
co-cultured with HepG2 or HepG2.2.1.5 cells. Anti-
PD-L1 antibodies (25 µg/mL) were added into the 
culture to block the interaction of  PD-1 and PD-L1 for 
48 h. Mouse IgG, as a control antibody, was used in the 
control group. After cultured for 48 h, the supernatants 
of  co-cultures were collected and stored at -80℃.
Analysis of cytokine secretion
Levels of  IL-2, IL-10 and INF-γ in the supernatants 
were measured by ELISA (Ucytech, Netherlands) 
following its manufacturer’s instructions.
Analysis of cytolytic activity
Cytolytic activity of  Jurkat cells was detected by MTT 
assay. After co-cultured for 48 h, Jurkat cells were 
isolated and MTT was added to incubate HepG2.2.1.5 
cells for 4 h, and bleached with DMSO. Finally, the 
cytolytic effect of  Jurkat cells on HepG2.2.1.5 cells was 
analyzed on Bio-Rad 450 (USA).
Statistical analysis
Results were expressed as mean ± SD or percentage. 
Comparison between groups was made using Student’s 
unpaired t-test. P < 0.05 was considered statistically 
significant. All analyses were performed using SPSS 13.0 
for Windows.
RESULTS
Enhancement of PD-1 expression on Jurkat cells 
PD-1 expression on Jurkat cells was determined by 
FACS analysis at 48 h after co-cultured with HepG2 
or HepG2.2.1.5 cells. Jurkat cells were also cultured 
solitarily as controls. The expression of  PD-1 was 
induced on Jurkat cells after co-culture with HepG2 
or HepG2.2.1.5 cells for 48 h, which was significantly 
higher on Jurkat cells co-cultured with hepatoma cells 
than on controls (P = 0.000, Table 1).
Function restoration of T cells
Supernatants were collected from the blocking and 
control groups. To investigate the influence of  cytokine 
production after PD-1/PD-L1 was blocked, the levels 
of  IL-2, IL-10 and INF-γ were measured. After PD-L1 
was blocked with specific antibodies, the levels of  IL-2, 
IL-10 and INF-γ were much higher in the blocking 
group than in the control group (P = 0.000, Table 2).
Furthermore, the effect of  the PD-1/PD-L1 pathway 
on cytolytic activity of  T cells was also investigated by 
MTT assay. The A value (0.29 ± 0.06) in the blocking 
group was much higher than that (0.19 ± 0.09) in the 
control group (P = 0.000).
DISCUSSION
Activation of  resting lymphocytes triggers expression of  
several products of  the immunoglobulin superfamily of  
genes. These activation-induced antigens are involved in 
Table 1  Up-regulated expression of PD-1 on T cells (n  = 24, 
mean ± SD)
Groups  PD-1(%)
Controls   0.70 ± 0.03
Co-cultured
HepG2 16.17 ± 2.5a
HepG2.2.1.5 17.43 ± 2.2b
aP = 0.000, bP = 0.000 vs control group.
www.wjgnet.com
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many physiological and pathological processes including 
cell proliferation (IL-2R), functional differentiation 
(CTLA-4), and apoptosis (Fas)[29,30]. The expression 
patterns of  these antigens are cell-specific, and have 
different regulation functions in different cells. PD-1, 
a member of  the CD28 family, which was isolated 
from apoptosis-induced T cell hybridoma in 1992[1], is 
expressed on activated T and B cells[2].
Agata et al[2] showed that PD-1 expresses on activated 
T and B cells. Anti-CD3 and concanavalin A (ConA) 
can stimulate its expression on thymocytes and T cells 
in spleen, and anti-IgM antibody can stimulate its 
expression on B cells in spleen. Vibhakar et al[31] also 
demonstrated that PD-1 mRNA and protein levels in 
Jurkat cells are up-regulated in a time-dependent manner 
during phorbo ester (TPA)-induced differentiation, 
indicating that lymphocyte activators can up-regulate 
PD-1 expression on lymphocytes. Since PHA is another 
T cell activating agent, the expression of  PD-1 in T 
cells can be detected after stimulation of  PHA. A time-
dependent up-regulation of  hPD-1 was also observed 
during PHA induction (data not shown), and was used 
as a stimulus of  Jurkat cells in our blocking experiment.
It was reported that, as an inhibitory co-stimulating 
molecular, PD-1 plays a role in immune regulation 
and is associated with the exhaustion of  effective T 
cells[32-34]. Barber et al[8] showed that, in chronic viral 
infection diseases, PD-1 is highly expressed on the 
exhausted LCMV-specific CD8 T cells and blocking the 
PD-1/PD-L1 interaction during the chronic phase of  
infection can efficiently reanimate the exhausted CD8 
T cells and promote clearance of  the persisting virus. 
In contrast, PD-1 expression is transiently induced 
and declines quickly to its basal level in acute LCMV-
Armstrong infection, thus promoting studies on other 
diseases associated with immune. Up-regulation of  PD-1 
expression on effective T cells leads to suppression of  
immune, which might be the underlying mechanism of  
immune evasion. PD-L1/PD-L2 expression in a variety 
of  tumor cells has been detected in human tumors[35,25-27], 
while PD-1 over-expression on tumor specific T cells 
has also been observed[23]. Interaction of  PD-1/PD-L1 
promotes apoptosis of  T cells, inhibits anti-tumor 
immune response of  T cells, and stimulates growth of  
tumors[27]. Obstructing the interaction of  PD-1/PD-L1 
enhances the function of  T cells, hampers development 
of  tumors[22,23,26]. In the present study, tumor cells 
induced expression of  PD-1 on T cells. After co-
cultured with hepatoma cells, PD-1 was expressed on T 
cells, but not expressed on Jurkat cells after cultured for 
48 h solitarily. PD-1 was expressed on T cells after Jurkat 
cells were co-cultured with the supernatant of  hepatoma 
cells (data not shown), suggesting that hepatoma cells 
can up-regulate the expression of  PD-1.
These findings lead to the clinical use of  PD-1 
blockers in the treatment of  tumors. In chronic 
infectious diseases, virus can induce the expression of  
PD-1 on T cell. However, the precise mechanism PD-1 
blockers still remains unclear. We observed the effect of  
tumor cells on PD-1 expression in T cells. Jurkat cells, 
a kind of  CD4+ T cells, can be used as target cells co-
cultured with hepatoma cells. FACS analysis showed that 
tumor cells could induce PD-1 expression on T cells. In 
this study, HepG2.2.1.5 cells transferring HBV genome 
and HepG2 cells not transferring HBV genome could 
induce PD-1 expression, suggesting that HBV has no 
effect on PD-1 expression on T cells.
In addition, the function of  PD-1 on T cells was 
also observed. Anti-PD-L1 antibody was used to block 
the interaction of  PD-1 and PD-L1. PD-1 was induced 
by PHA, and PD-L1 was expressed in HepG2.2.1.5 
cells identified by FACS (data not shown). Jurkat 
cells after activated by PHA were co-cultured with 
HepG2.2.1.5cells. Antibodies against human PD-L1 
were added into the co-culture system as a blocking 
group, while mouse IgG was added as a control group. 
The levels of  cytokines including IL-2, INF-γ and 
IL-10 in culture supernatant and the cytolytic activity 
of  T cells were detected, which were significantly 
elevated in blocking group compared to the control 
group, suggesting that both Th1 and Th2 have immune 
responses can be restored and PD-1/PD-L that 
negatively regulates the immune reaction by blocking 
the PD-1/PD-L pathway can recover the function of  T 
cells, which introduces a new theory of  tumor immune 
evasion. This new mechanism of  tumor immunology 
might provide a novel target for therapy.
 COMMENTS
Background
Programmed cell death-1 (PD-1), originally isolated from apoptotic T cells, is 
a 55-kDa transmembrane protein with an extracellular IgV-like domain and a 
97-amino acid cytoplasmic tail containing an immunotyrosine inhibitory motif 
(ITIM) and an immunotyrosine switch motif (ITSM). PD-1 has two ligands: 
PD-L1 and PD-L2, which are members of the CD28/B7 superfamily. The 
expressions of CD28, CTLA-4, and ICOS are limited in T cells. PD-1 can be 
expressed on activated T, B and myeloid cells. The expression of PD-L1 has 
been detected in many organ tissues, such as heart, lung, pancreas, muscle, 
and placenta, including lymphocytes and non-lymphocytes. The expression of 
PD-L2 is restricted in DC and macrophages.
Research frontiers
Recent findings suggest that PD-1/PD-L pathway plays a role in regulating 
tolerance and autoimmunity. The role of PD-1 and its ligands in regulating 
human autoimmune disease, infectious diseases and tumors has been 
investigated. Interaction of PD-1 and PD-L has been found to be important for 
controlling effective T cells. Significantly increased expression of PD-1 and 
PD-L1 in T and B macrophages/dendritic cells and tumor cells, associated with 
T-cell exhaustion and disease progression, immobilized auto-antibodies to 
PD-L, can stimulate T cell proliferation, cytokine production, and programmed 
cell death. The up-regulation of PD-L1 in tumors and PD-1 in T cells can lead to 
immune tolerance.
Innovations and breakthroughs
The present study demonstrated the effect of hepatoma cells on up-regulating 
Groups       IL-2   IFN-γ    IL-10
Control group 102.9 ± 53.0 39.3 ± 4.2 34.6 ± 13.7
Blocking group 202.9 ± 53.0c 88.6 ± 4.6d 63.7 ± 13.4e
Table 2  Secretion of cytokines by T cells (pg/mL, n  = 24, 
mean ± SD)
cP = 0.000, dP = 0.000, eP = 0.000 vs control group.
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the expression of PD-1 in T cells. In addition, the function of PD-1 in T cells was 
assessed, showing that the cytokine production and cytotoxicity of T cells can 
be elevated by blocking the interaction of PD-1 and PD-L1.
Applications
The up-regulation of PD-1 in T cells by hepatoma cells has led to a new 
hypothesis that the PD-1 and PD-L pathway may be a means by which tumors 
evade T cell recognition. Manipulation of the PD-1 pathway can enhance 
immune response, and may become a novel strategy for the treatment of 
tumors.
Terminology
MTT is a direct mono-nuclear cell direct cytotoxicity assay used to detect the 
cytotoxicity of T cells. PHA is a T cell stimulus that can activate T cells. G418, 
a kind of antibiotics, is used in selective cell culture medium. G418 must be 
added into culture medium of HepG2.2.1.5 cells to support the selective survival 
of HepG2.2.1.5 cells.
Peer review
This is a very interesting study, showing that HCC-induced modulation of PD-1 
expression in T-cells might contribute to immune evasion. This concept might 
hold its promise for new therapeutic interventions. The experiments support the 
authors’ claim.
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